GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Cash Flow from Investing

Cadence Pharmaceuticals, (FRA:QEW) Cash Flow from Investing : €12.08 Mil (TTM As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2013, Cadence Pharmaceuticals, spent €0.31 Mil on purchasing property, plant, equipment. It gained €0.00 Mil from selling property, plant, and equipment. It spent €0.00 Mil on purchasing business. It gained €0.00 Mil from selling business. It spent €0.00 Mil on purchasing investments. It gained €0.00 Mil from selling investments. It paid €0.00Mil for net Intangibles purchase and sale. And it paid €0.00 Mil for other investing activities. In all, Cadence Pharmaceuticals, spent €0.31 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2013.


Cadence Pharmaceuticals, Cash Flow from Investing Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Cash Flow from Investing Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.75 -16.52 -22.15 30.15 11.42

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 11.29 1.03 0.06 -0.31

Cadence Pharmaceuticals, Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Cadence Pharmaceuticals,'s Cash Flow from Investing for the fiscal year that ended in Dec. 2013 is calculated as:

Cadence Pharmaceuticals,'s Cash Flow from Investing for the quarter that ended in Dec. 2013 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadence Pharmaceuticals,  (FRA:QEW) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Cadence Pharmaceuticals,'s purchase of property, plant, equipment for the three months ended in Dec. 2013 was €-0.31 Mil. It means Cadence Pharmaceuticals, spent €0.31 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Cadence Pharmaceuticals,'s sale of property, plant, equipment for the three months ended in Dec. 2013 was €0.00 Mil. It means Cadence Pharmaceuticals, gained €0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Cadence Pharmaceuticals,'s purchase of business for the three months ended in Dec. 2013 was €0.00 Mil. It means Cadence Pharmaceuticals, spent €0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Cadence Pharmaceuticals,'s sale of business for the three months ended in Dec. 2013 was €0.00 Mil. It means Cadence Pharmaceuticals, gained €0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Cadence Pharmaceuticals,'s purchase of investment for the three months ended in Dec. 2013 was €0.00 Mil. It means Cadence Pharmaceuticals, spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Cadence Pharmaceuticals,'s sale of investment for the three months ended in Dec. 2013 was €0.00 Mil. It means Cadence Pharmaceuticals, gained €0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Cadence Pharmaceuticals,'s net Intangibles purchase and sale for the three months ended in Dec. 2013 was €0.00 Mil. It means Cadence Pharmaceuticals, paid €0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cadence Pharmaceuticals,'s cash from discontinued investing activities for the three months ended in Dec. 2013 was 0.00 Mil. It means Cadence Pharmaceuticals, paid €0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cadence Pharmaceuticals,'s cash from other investing activities for the three months ended in Dec. 2013 was €0.00 Mil. It means Cadence Pharmaceuticals, paid €0.00 Mil for other investing activities.


Cadence Pharmaceuticals, Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines